Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma

Diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms

Masakazu Kojika, Genichiro Ishii, Junji Yoshida, Mituyo Nishimura, Tomoyuki Hishida, Shu Ji Ota, Yukinori Murata, Kanji Nagai, Atsushi Ochiai

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

There are only a few immunohistochemical markers that are useful for differentiating thymic carcinomas from type B3 thymomas. The purpose of this study is to examine the additional markers that would be useful for differentiating between thymic carcinoma and thymoma type B3. We performed a tissue microarray analysis of surgically resected thymic tumor specimens from12 cases of thymic carcinoma, 7 cases of type B3 thymoma, and 68 cases of other types of thymoma. Immunostaining using 49 antibodies was scored based on staining intensity and the percentage of cells that stained positive. Seven proteins that were selected by the staining scores, namely, GLUT-1 (167 vs 4), CA-IX (110 vs 15), c-kit (162 vs 44), CD5 (33 vs 0), MUC-1 (54 vs 0), CEA (42 vs 0), and CK18 (110 vs 42), were significantly higher in the thymic carcinomas than in the type B3 thymomas. The staining sensitivity and specificity of the antibodies for thymic carcinoma were GLUT-1, sensitivity 72% and specificity 100%; CA-IX, 58 and 71%; c-kit, 72 and 85%; CD5, 33 and 100%; CK18, 58 and 71%; MUC-1, 25 and 100%; and CEA, 33 and 100%. Glucose transporter 1 (GLUT-1) is the best marker for thymic carcinoma because it had the highest sensitivity and specificity. Positive immunostaining for a combination of three markers, namely, GLUT-1, CD5, and CEA, enabled differentiation of thymic carcinoma with 91.6% sensitivity and 100% specificity. In conclusion, we identified GLUT-1 as an additional marker that will be useful for differentiating thymic carcinoma from type B3 thymoma, especially in biopsy specimens that have been crushed or are otherwise difficult to examine morphologically in thymic tumors.

Original languageEnglish
Pages (from-to)1341-1350
Number of pages10
JournalModern Pathology
Volume22
Issue number10
DOIs
Publication statusPublished - 2009 Oct
Externally publishedYes

Fingerprint

Thymus Neoplasms
Thymoma
Glandular and Epithelial Neoplasms
Facilitative Glucose Transport Proteins
Differential Diagnosis
Sensitivity and Specificity
Staining and Labeling
Tissue Array Analysis
Antibodies

Keywords

  • CA-IV
  • GLUT-1
  • Thymic carcinoma
  • Thymoma
  • Type B3 thymoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma : Diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms. / Kojika, Masakazu; Ishii, Genichiro; Yoshida, Junji; Nishimura, Mituyo; Hishida, Tomoyuki; Ota, Shu Ji; Murata, Yukinori; Nagai, Kanji; Ochiai, Atsushi.

In: Modern Pathology, Vol. 22, No. 10, 10.2009, p. 1341-1350.

Research output: Contribution to journalArticle

Kojika, Masakazu ; Ishii, Genichiro ; Yoshida, Junji ; Nishimura, Mituyo ; Hishida, Tomoyuki ; Ota, Shu Ji ; Murata, Yukinori ; Nagai, Kanji ; Ochiai, Atsushi. / Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma : Diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms. In: Modern Pathology. 2009 ; Vol. 22, No. 10. pp. 1341-1350.
@article{caf1893552b44362b857e854b5b60942,
title = "Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: Diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms",
abstract = "There are only a few immunohistochemical markers that are useful for differentiating thymic carcinomas from type B3 thymomas. The purpose of this study is to examine the additional markers that would be useful for differentiating between thymic carcinoma and thymoma type B3. We performed a tissue microarray analysis of surgically resected thymic tumor specimens from12 cases of thymic carcinoma, 7 cases of type B3 thymoma, and 68 cases of other types of thymoma. Immunostaining using 49 antibodies was scored based on staining intensity and the percentage of cells that stained positive. Seven proteins that were selected by the staining scores, namely, GLUT-1 (167 vs 4), CA-IX (110 vs 15), c-kit (162 vs 44), CD5 (33 vs 0), MUC-1 (54 vs 0), CEA (42 vs 0), and CK18 (110 vs 42), were significantly higher in the thymic carcinomas than in the type B3 thymomas. The staining sensitivity and specificity of the antibodies for thymic carcinoma were GLUT-1, sensitivity 72{\%} and specificity 100{\%}; CA-IX, 58 and 71{\%}; c-kit, 72 and 85{\%}; CD5, 33 and 100{\%}; CK18, 58 and 71{\%}; MUC-1, 25 and 100{\%}; and CEA, 33 and 100{\%}. Glucose transporter 1 (GLUT-1) is the best marker for thymic carcinoma because it had the highest sensitivity and specificity. Positive immunostaining for a combination of three markers, namely, GLUT-1, CD5, and CEA, enabled differentiation of thymic carcinoma with 91.6{\%} sensitivity and 100{\%} specificity. In conclusion, we identified GLUT-1 as an additional marker that will be useful for differentiating thymic carcinoma from type B3 thymoma, especially in biopsy specimens that have been crushed or are otherwise difficult to examine morphologically in thymic tumors.",
keywords = "CA-IV, GLUT-1, Thymic carcinoma, Thymoma, Type B3 thymoma",
author = "Masakazu Kojika and Genichiro Ishii and Junji Yoshida and Mituyo Nishimura and Tomoyuki Hishida and Ota, {Shu Ji} and Yukinori Murata and Kanji Nagai and Atsushi Ochiai",
year = "2009",
month = "10",
doi = "10.1038/modpathol.2009.105",
language = "English",
volume = "22",
pages = "1341--1350",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma

T2 - Diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms

AU - Kojika, Masakazu

AU - Ishii, Genichiro

AU - Yoshida, Junji

AU - Nishimura, Mituyo

AU - Hishida, Tomoyuki

AU - Ota, Shu Ji

AU - Murata, Yukinori

AU - Nagai, Kanji

AU - Ochiai, Atsushi

PY - 2009/10

Y1 - 2009/10

N2 - There are only a few immunohistochemical markers that are useful for differentiating thymic carcinomas from type B3 thymomas. The purpose of this study is to examine the additional markers that would be useful for differentiating between thymic carcinoma and thymoma type B3. We performed a tissue microarray analysis of surgically resected thymic tumor specimens from12 cases of thymic carcinoma, 7 cases of type B3 thymoma, and 68 cases of other types of thymoma. Immunostaining using 49 antibodies was scored based on staining intensity and the percentage of cells that stained positive. Seven proteins that were selected by the staining scores, namely, GLUT-1 (167 vs 4), CA-IX (110 vs 15), c-kit (162 vs 44), CD5 (33 vs 0), MUC-1 (54 vs 0), CEA (42 vs 0), and CK18 (110 vs 42), were significantly higher in the thymic carcinomas than in the type B3 thymomas. The staining sensitivity and specificity of the antibodies for thymic carcinoma were GLUT-1, sensitivity 72% and specificity 100%; CA-IX, 58 and 71%; c-kit, 72 and 85%; CD5, 33 and 100%; CK18, 58 and 71%; MUC-1, 25 and 100%; and CEA, 33 and 100%. Glucose transporter 1 (GLUT-1) is the best marker for thymic carcinoma because it had the highest sensitivity and specificity. Positive immunostaining for a combination of three markers, namely, GLUT-1, CD5, and CEA, enabled differentiation of thymic carcinoma with 91.6% sensitivity and 100% specificity. In conclusion, we identified GLUT-1 as an additional marker that will be useful for differentiating thymic carcinoma from type B3 thymoma, especially in biopsy specimens that have been crushed or are otherwise difficult to examine morphologically in thymic tumors.

AB - There are only a few immunohistochemical markers that are useful for differentiating thymic carcinomas from type B3 thymomas. The purpose of this study is to examine the additional markers that would be useful for differentiating between thymic carcinoma and thymoma type B3. We performed a tissue microarray analysis of surgically resected thymic tumor specimens from12 cases of thymic carcinoma, 7 cases of type B3 thymoma, and 68 cases of other types of thymoma. Immunostaining using 49 antibodies was scored based on staining intensity and the percentage of cells that stained positive. Seven proteins that were selected by the staining scores, namely, GLUT-1 (167 vs 4), CA-IX (110 vs 15), c-kit (162 vs 44), CD5 (33 vs 0), MUC-1 (54 vs 0), CEA (42 vs 0), and CK18 (110 vs 42), were significantly higher in the thymic carcinomas than in the type B3 thymomas. The staining sensitivity and specificity of the antibodies for thymic carcinoma were GLUT-1, sensitivity 72% and specificity 100%; CA-IX, 58 and 71%; c-kit, 72 and 85%; CD5, 33 and 100%; CK18, 58 and 71%; MUC-1, 25 and 100%; and CEA, 33 and 100%. Glucose transporter 1 (GLUT-1) is the best marker for thymic carcinoma because it had the highest sensitivity and specificity. Positive immunostaining for a combination of three markers, namely, GLUT-1, CD5, and CEA, enabled differentiation of thymic carcinoma with 91.6% sensitivity and 100% specificity. In conclusion, we identified GLUT-1 as an additional marker that will be useful for differentiating thymic carcinoma from type B3 thymoma, especially in biopsy specimens that have been crushed or are otherwise difficult to examine morphologically in thymic tumors.

KW - CA-IV

KW - GLUT-1

KW - Thymic carcinoma

KW - Thymoma

KW - Type B3 thymoma

UR - http://www.scopus.com/inward/record.url?scp=70349705902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349705902&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2009.105

DO - 10.1038/modpathol.2009.105

M3 - Article

VL - 22

SP - 1341

EP - 1350

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 10

ER -